How do you decide?' Cancer patients die waiting for CAR-T therapy

“And people are dying. About 20% of all our patients together are actually dying before they can get CAR-T,” said Krina Patel, director of the myeloma cell therapy program at MD Anderson.

Yescarta for Relapsed or Refractory Large B-Cell Lymphoma - NCI

Patient Monitoring Post-CAR T Therapy using Flow Cytometry & Functional Proteomic Analysis

Manufacturing challenge leads to death in CAR-T trial

How CAR T-Cell Therapy 'Cured' 2 Cancer Patients

Blood cancer treatment: How multiple myeloma became nearly curable

The Challenges and Benefits of End-To-End CAR T-Cell Therapy

Why Choose CAR T-cell Therapy for Multiple Myeloma in Israel

How do you decide?' Cancer patients die waiting for CAR-T therapy

CAR-T therapies are manufactured for each individual patient

New specialized cancer treatment program coming to Manitoba